Clinical trials: Intravitreal Injection
Choroidal Neovascularization
Bevacizumab Effect on Blood Velocity
Retinal blood flow velocity is affected by Bevacizump intravitreal injection. This effect is correlated to treatment success.
- Trial name
- NCT01298440
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Optical Imaging, Ltd.
Stargardt Disease
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
The purpose of the study is to evaluate the safety and effects of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) in Subjects with Stargardt Disease
- Trial name
- STARLIGHT (NCT05417126)
- Testing
- Gene Therapy-vMCO-010
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Nanoscope Therapeutics Inc.
Macular Edema, Branch Retinal Vein Occlusion
Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion
Branch retinal vein occlusion (BRVO) is a common retinal vascular disease occurring in a significant number of individuals older than 50 years.The most common cause of visual disturbance in BRVO patients is macular edema, which…
- Trial name
- NCT00612261
- Testing
- Arteriovenous Crossing Sheathotomy, Intravitreal Triamcinolone Acetonide Injection
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Non-Proliferative Diabetic Retinopathy
Intravitreal and Intracameral DEX in NPDR
To investigate the effects of intravitreal and intracameral injection of dexamethasone during cataract phacoemulsification in patients with mild to moderate non-proliferative diabetic retinopathy
- Trial name
- NCT06951087
- Testing
- Dexamethasone sodium phosphate
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Affiliated Hospital of Nantong University
Retina Disease, Retinopathy of Prematurity
Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity
Despite advances in the neonatal intensive care units, retinopathy of prematurity (ROP) has become a common reason for blindness and visual disabilities in premature infants so that it accounts for about 5% and 30% of such…
- Conditions
- Retina Disease, Retinopathy of Prematurity, Ranibizumab
- Trial name
- NCT05701124
- Testing
- Ranibizumab (0.25 mg/0.025 mL)
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Zagazig University
Age-Related Macular Degeneration
IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD
This is a prospective, single-blind, randomized study to evaluate intravitreal aflibercept injection (IAI) versus sham as prophylaxis against conversion to neovascular age-related macular degeneration (AMD) in "high-risk"…
- Trial name
- PRO-CON (NCT02462889)
- Testing
- Intravitreal aflibercept injection
- Where
- 4 sites in United States
- Volunteers
- 128 people
- Sponsor
- Jeffrey S Heier
Retinopathy of Prematurity Both Eyes
Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity
Retinopathy of prematurity (ROP) with inadequate growth and development of retinal blood vessels in premature infants is one of the foremost reasons for childhood blindness.
- Trial name
- NCT05033106
- Testing
- Bevacizumab, Ranibizumab
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Zagazig University
Hippel-Lindau Disease
EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
This study will test the ability of the experimental drug EYE001 to reduce retinal thickening and improve vision in patients with Von Hippel-Lindau syndrome (VHL).
- Trial name
- NCT00056199
- Testing
- EYE001
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Maculopathy
Retinal Oximtery Following Treatment for Diabetic Maculopathy
The investigators believe that oxygen saturation measurements in the retina may provide more information on how well the retina is working and may detect problems in the retina earlier than the fundus fluorescein angiography…
- Trial name
- NCT01549132
- Volunteers
- 45 people
- Sponsor
- East Kent Hospitals University NHS Foundation Trust
Retinal Telangiectasis, Coats Disease
Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
Coats disease is a predominantly unilateral progressive retinal vascular disease, characterized by retinal telangiectasias with intra- or subretinal exudate deposits, which can lead to retinal detachment and one-sided blindness.
- Trial name
- COATS-VEGF (NCT03940690)
- Testing
- Anti-VEGF injections of bevacizumab, Laser
- Where
- 6 sites in France
- Volunteers
- 18 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Retinitis Pigmentosa, Usher Syndrome Type 2
Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
The purpose of this study is to evaluate the efficacy safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- NCT05158296
- Testing
- Ultevursen
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 7 people
- Sponsor
- Laboratoires Thea
Diabetic Macular Edema
Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema
Purpose: to evaluate the effect of intravitreal injection of tissue plasminogen activator(tPA) in treatment of refractory diabetic macular edema(DME).
- Trial name
- NCT01141881
- Testing
- Tissue Plasminogen Activator,bevacizumab ,follow up
- Where
- Iran
- Sponsor
- Mashhad University of Medical Sciences
Stargardt Disease
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
The current study is a non-interventional long-term safety follow-up of the subjects who completed STARLIGHT, in accordance with FDA guidance on recipients of human gene therapy products.
- Trial name
- SUSTAIN (NCT06048185)
- Testing
- Gene Therapy Product-MCO-010
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Nanoscope Therapeutics Inc.
Optic, Atrophy, Hereditary, Leber
Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)
The goal of this clinical trial is to assess the effectiveness of GS010, a gene therapy, in improving the visual outcome in participants with Leber Hereditary Optic Neuropathy (LHON) due to the G11778A ND4 mitochondrial mutation…
- Trial name
- REVERSE (NCT02652780)
- Testing
- GS010
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 37 people
- Sponsor
- GenSight Biologics
Central Retinal Vein Occlusion
Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)
This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute central retinal vein occlusion.
- Trial name
- NCT01178697
- Testing
- Bevasizumab, Triamcinolone Acetonide
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Early OCT Biomarker Changes in Response to Anti-VEGF
Early Changes in OCT Biomarkers After the First Intravitreal Anti-VEGF Injection in Treatment-naïve DME
A retrospective, observational, hospital-based study which will be conducted in the Department of Ophthalmology, Sohag University Hospital, Egypt.
- Trial name
- NCT06841250
- Testing
- intravitreal injection of anti-VEGF
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Retinal Astrocytic Hamartoma
Sirolimus for Retinal Astrocytic Hamartoma
A single patient study using intravitreal Sirolimus to treat a patient with multiple retinal astrocytic hamartomas (RAH) of both eyes.
- Trial name
- NCT04707209
- Testing
- Sirolimus
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- The Hospital for Sick Children
Endophthalmitis, Endophthalmitis Postoperative
Phacovitrectomy Versus Pars Plana Vitrectomy Alone for Post-Intravitreal Injection Endophthalmitis
This prospective comparative interventional study evaluated the anatomical and visual outcomes of phacovitrectomy versus pars plana vitrectomy (PPV) alone in patients with post-intravitreal injection endophthalmitis.
- Conditions
- Endophthalmitis, Endophthalmitis Postoperative, Intravitreal Injection Patients
- Trial name
- NCT07717944
- Testing
- Phacovitrectomy, Pars plana vitrectomy
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Benha University
Blind Painful Eye, Refractory Glaucoma
Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye
The purpose of this study is to evaluate the efficacy of intravitreal triamcinolone and retrobulbar chlorpromazine as alternatives in the management of ocular pain in blind eyes.
- Conditions
- Blind Painful Eye, Refractory Glaucoma, Control of Pain Through Drug Injection
- Trial name
- NCT01404364
- Testing
- Triamcinolone, Chlorpromazine
- Where
- Brazil
- Volunteers
- 36 people
- Sponsor
- Hospital Governador Celso Ramos
Retinoblastoma
Intravitreal Injections of Melphalan for Retinoblastoma
Retinoblastoma treatment has become more and more focused in the last years. New treatments developed by Dr. Kaneko from Japan in 1995 are now being tested in clinical trials.
- Trial name
- NCT01558960
- Testing
- IVit Melphalan
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Hadassah Medical Organization